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Background: Ovarian cancer (OC) is the sixth most common cancer in women. Currently, carboplatin/
paclitaxel ± bevacizumab is the cornerstone of front-line treatment. Conversely, the therapeutic options for
recurrent or progressive disease are not well defined. For platinum-sensitive patients the best therapeutic
approach is still a re-challenge with a platinum-based regimen. Pegylated liposomal doxorubicin (PLD), is
considered one of the most active therapeutic options for recurrent or progressive OC. In this retrospective
mono-institutional analysis, we evaluated the impact of PLD on the outcome of OC patients.
Patients and methods: We performed the retrospective study on a cohort of 108 patients with
histologically confirmed serous papillary OC, followed at our Institution between 2001 and 2011. 80 patients
were in stage III/IV and 55 of them received a second-line treatment. Thirty patients were treated with PLD.
Both groups (PLD-treated versus PLD-untreated) underwent a median of 3 treatment lines and were
prognostically balanced. The median follow-up was 60 months. Survival endpoints, toxicity and correlations
between patients’ baseline characteristics and treatment efficacy were evaluated.
Results: Patients who had undergone PLD treatment (PLD group) showed a median overall survival (OS) of 45
months as compared to 65 months of patients not treated with PLD (PLD-free group) (HR 2.50 [0.95-6.67; p = 0.06]).
Moreover, the median progression-free survival was 6 months in the PLD group versus 10 months in the PLD-free
group (HR 1.75 [0.94-3.34; p = 0.07]). The overall objective response rate in II line treatment was 43% (13% in PLD group
versus 57% in PLD-free group). Furthermore, we investigated survival endpoints in platinum-refractory patients who
received PLD at least once during the course of disease. No OS advantage was achieved by PLD administration when
compared to other therapeutic options (30 versus 32 months; HR 1.16 [0.31-4.34; p = 0.81]). No difference in term of
toxicity was observed among different groups.
Conclusions: No evidence of superiority if PLD was compared to alternative agents was found in this analysis,
particularly in the platinum-refractory setting. Our findings indicate a modest therapeutic activity of PLD in OC. Analysis
of cost/benefit of PLD in OC is eagerly awaited.
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Ovarian cancer (OC) is the sixth most common malignancy
in women [1]. Serous papillary OC, the most frequent his-
totype, is the leading cause of death for gynecological
tumors and represents 5% of cancer-related mortality in
women in the western world. The overall 5-years survival
rate is 30% [2] and about 2/3 of OC patients are diag-
nosed in an advanced stage (stage II with residual disease,
stage III and stage IV). FIGO (International Federation of
Gynecology and Obstetrics) stage, surgical residual disease
and histological grade, at diagnosis, are known to influence
the outcome of these patients [3,4].
In the last years, a variety of clinical trials failed to dem-
onstrate advantages of the addition of a third cytotoxic
drug to the standard doublet [5,6] and currently, carbopla-
tin/paclitaxel ± bevacizumab is the cornerstone of front-
line treatment [7,8]. Conversely, the therapeutic scenario
for recurrent or progressive disease remains still undefined.
Second-line therapy is selected taking into account the
response to front-line platinum-based treatment. Patients
who relapse within 6 months from the last platinum-based
treatment course are considered platinum-refractory, while
patients who relapse at least 12 months after the last
chemotherapy course are considered platinum-sensitive.
Furthermore, it is common practice to consider a third
group of patients, the “partially platinum-sensitive
patients”, as those who relapse between 6 and 12
months [9,10]. This clinical classification appears to
better represent the clinical outcome of serous papillary
OC as compared to mucinous or clear cell or low grade
endometrioid OC [11], probably due to a different em-
bryologic origin and pathogenesis. It has been hypothe-
sized that serous papillary OC directly arises from the
ovary and tube epithelium while endometrioid or mu-
cinous may derive from endometrial or gastrointestinal
embrional implants, respectively [12,13]. Moreover, it
has been described a strong association between platinum-
sensitivity and high grade serous papillary OC, harboring
p53 mutation and somatic or germline mutations of
BRCA1 [13]. This observation founds its molecular basis in
the failure of the DNA repair homologous recombination
mechanisms (due to loss of BRCA1 function) to restore
double-strand breaks induced by platinum compounds,
and has been described in experimental in vitro and in vivo
models [14-18].
Concerning the second-line therapy for platinum-
sensitive patients, a re-challenge with a carboplatin-
based regimen is considered the optimal approach
[19]. Two randomized trials (GOG 182 and Calypso
trials), that included all OC histotypes, demonstrated an
advantage for carboplatin/PLD combination as com-
pared to carboplatin/paclitaxel in both front-line and
second-line therapy in terms of progression free survival
(PFS) [6,20-23]. PLD became therefore a primary optionin clinical practice, taking also in account the good
safety profile.
On the other hand, no standard approach for second
line treatment exists for platinum-refractory patients
[24,25]. In the past years, different phase II/III trials
investigated the activity of several drugs such as PLD,
topotecan, etoposide, taxanes, gemcitabine, oxaliplatin in
this group of patients; however clinical results were
modest with low response rates (RR) and without a sig-
nificant impact in terms of overall survival [26-29]. In
this setting, the use of PLD is supported only by sub-
group analysis of different clinical trials, where even in
the absence of a significant superiority in term of sur-
vival a better toxicity profile was found [26-29]. A phase
III trial, specifically designed for platinum-refractory set-
ting, did not show any advantage for PLD in term of
overall survival (OS) and toxicity when compared to
gemcitabine [28].
The purpose of our retrospective analysis is to assess
the actual impact of PLD in the management of OC
patients in our Institution.
Patients and methods
We performed a retrospective analysis on 108 patients
with confirmed histology of serous papillary high grade
OC, followed at our Institution between 2001 and 2011.
Clinical data have been retrieved from medical records
and entered into an electronic database. Eligibility criteria
included histologically-confirmed diagnosis of serous pap-
illary adenocarcinoma, age >18 years, ECOG performance
status 0–1, adequate renal and liver function and no major
comorbidities. 80/108 (74%) patients were in stage III/IV
and 55 of them (51%) received a second-line treatment.
Different OC prognostic factors were evaluated in our
series: age, performance status, comorbidities, previous
malignancies, date of first diagnosis, stage, grade, and
presence/absence of metastases at diagnosis, site of metas-
tases, CA125 levels (baseline, during chemotherapy, at
eventual disease relapse), first-line chemotherapy with
response and toxicity, eventual II look surgery, any subse-
quent line of chemotherapy. Response to chemotherapy
has been reported according to Response Evaluation
Criteria In Solid Tumors (RECIST). Patients were moni-
tored every 3 months. When disease progression was
thought for increasing CA125 or for the onset of clinical
symptoms, all patients underwent total body computed
tomography scan (TC scan) and/or other imaging proce-
dures to assess the status of disease. For PLD efficacy ana-
lysis, patients were divided into 2 subgroups: i) 30 patients
treated with PLD for recurrent or progressive disease, and
ii) 25 patients never treated with PLD, which were evalu-
ated for survival and treatment endpoints. In the decision-
making, PLD treatment was selected on the basis of
platinum-sensitivity and toxicities reported to prior
Table 1 Main patient characteristics
Characteristics Number of patients (%)
Median age (59 years)
-Age between 18–59 years 55 (51)
-Age > 59 years 53 (49)




Stage at diagnosis (n)
-Stage I 22 (20)
-Stage II 6 (5)
-Stage III 49 (45)





Median value of CA 125
CA 125 ≥ 205 46 (42)
Ca 125 < 205 43 (40)
D-dimer
-Hig D-dimer value 17 (16)
-Low D-dimer value 15 (14)
Comorbidity
-No comorbidity 31 (29)
-Grade 1 comorbity 10 (9)







Neoadjuvant treatment 15 (14)
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40–50 mg/mq q28 days for a median of 6–8 cycles,
according to the international guidelines. The use of
granulocyte colony stimulating factors and erythro-
cyte stimulating factors was at physician choice. Both
OC patient groups underwent a mean of 3 treatment lines
with a median follow-up of 60 months. The study was per-
formed according to the bioethics standard of our Institu-
tion and all patients at first admission visit had provided
consent to anonymous data management for clinical
research.
Statistical analysis
In order to avoid selection bias, data were collected by two
independent investigators (N.S. and D.C.) and the missing
information have been subsequently discussed and solved
by the aid of an arbiter (P.T.). Primary endpoint was OS in
all patients and specifically in patients treated with PLD in
all treatment lines (second-line and/or subsequent lines) as
compared to no-PLD treatment. Other endpoints were
PFS, response rate (RR) and toxicity. OS was defined as the
time elapsed between the start of treatment and the date of
death. PFS is intended as the time from start of treatment
to progression or death. The time to relapse of ovarian
cancer after platinum treatment was assessed by CA125
and imaging (CA125- or image confirmed-PFS which
undergone separate analysis) while responses were evalu-
ated by RECIST criteria. The differences between the
patients’ baseline characteristics were analyzed with the
Wilcoxon test and the method of Chi-square. Differences
were considered statistically significant with p value ≤0.05.
Survival analysis and correlations between patients’ base-
line characteristics and toxicity were evaluated by Kaplan-
Meier curves and Log-Rank test statistics in the univariate
analysis. Subsequently variables with significant p value
were entered into a multivariate analysis model according
to Cox proportional hazards model to analyze the role of
confounding factors [30]. The relative hazard ratios (HR)
with 95 percent confidence intervals (95% CIs) were calcu-
lated using SPSS (version 19) statistical package.
Results
In Table 1, the baseline characteristics of 108 patients
enrolled in our retrospective analysis are reported. All
patients were treated at our University Cancer Center
from January 2001 to December 2011. Median age was
59 years, median ECOG PS= 0. 80% of patients pre-
sented in advanced stage with lymph node involvement
(FIGO IIIC) and 20% of them had grade 2 histology and
70% grade 3. Median OS in patients in early stage of dis-
ease was 80 months, with a more favorable outcome
as compared to literature data. Age, performance status
and stage at diagnosis were comparable to inclusion cri-
teria of major trials. About 60% of patients presentedwith comorbidities (eg, hypertension, diabetes mellitus
type 2) grade 2 according to CTCAE criteria v 4.0. The
median value of baseline CA125 (205 IU/ml) was calcu-
lated in the whole study population, and the patients were
divided into 2 groups according to this cut-off. In a small
subgroup of 32 patients it was possible to investigate the
value of D-dimer as prognostic factor. 51% of the patient
received a second-line treatment and about 25% under-
went a third-line treatment. 20% of the patients under-
went second-look surgery.
Among 55 patients who received second-line chemo-





















Figure 2 Kaplan Meier overall survival: D-dimer and
PLD treatment.
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patients platinum-sensitive disease. Median OS of patients
with recurrent disease was 48 months and median first
line PFS was 12 months (Figure 1). Subsequently, we
investigated the impact of each prognostic factor on sur-
vival. In particular, patients with the lower CA125 value at
diagnosis had a better outcome in terms of PFS (17 vs 12
months) with an HR 0.40 (0.21 to 0.79, p = 0.008). This
finding was also confirmed in OS (62 vs 35 months, HR
0.45 CI: 0.20 to 0.99, p = 0.049). OS evaluated according
to platinum response was 30 months for refractory
patients, 80 months for patients partially platinum-
sensitive while median survival was still not reached for
platinum-sensitive patients . A D-dimer value in normal
ranges was associated (even if the statistical significance
was not reached) with a longer PFS (28 vs 13 months; HR
0.35 CI: 0.06 to 1.77, p = 0.07) (Figure 2).
We compared the outcome of patients treated with
PLD along the course of their disease with control arm
(patients distribution showed in Table 2) represented by
patients never treated with this agent but treated with
other drugs such as topotecan, gemcitabine, etoposide.
Among them, 37% had a platinum-refractory status and
43% had partially platinum-sensitive status. Both groups
shared similar baseline characteristics after the first line
treatment (Table 3). PFS was 6 months in PLD group
and 10 months in control arm (HR 0.57 CI: 0.30 to 1.06,
p = 0.07). OS was 45 months vs 65 months respectively
(HR 0.40 CI: 0.15 to 1.05, p =0.06) (Figure 3). We per-
formed a further exploratory analysis to compare sur-
vival between patients treated with PLD in second line






















Figure 1 Kaplan Meier overall survival and response to
platinum treatment.(Figure 4). This analysis revealed an advantage in term
of OS in the PLD-free series (35 vs 48 months). These
results were not due to an asymmetric distribution of
platinum-sensitive patients between PLD and no-PLD
groups. Overall RR in II line treatment was 43% (13% in
PLD group vs 57% in PLD-free group).
Toxicity
Table 4 reports toxicities recorded for PLD arm com-
pared to other treatment arm in our study. About 27%
of patients treated with PLD experienced grade 2 or 3
toxicities. The most common toxicities were neutropenia
(14%), thrombocytopenia (7%), anemia (1%), hand–foot
syndrome (5%), mucositis (5%). In control arm, toxicities
were comparable with literature data on the basis of
selected treatment.
Discussion
The results of our retrospective study do no support the
common belief that PLD is the first choice for recurrent
or progressive OC treatment. Indeed, in our analysis, we
were unable to demonstrate advantages in terms of PFS
and OS for PLD administration at any time along theTable 2 PLD use beyond first line treatment
Patients (%)
II line treatment 55
○ Pld 22 (40%)
○ other therapy 33 (60%)
Among all treatment lines
○ Pld 30 (54%)
○ other therapy 25 (46%)
Table 3 Treatment choice on the basis of platinum




(No PLD) 25 patients
Platinum sensitive 9 (30 %) 8 (32%)
Partially-platinum
sensitive
10 (33%) 5 (20%)


















II line treatment (PLD group)
II line treatment (no-PLD group)
Figure 4 Kaplan Meier overall survival: PLD treatment in II
line treatment.
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took benefit from PLD more than the platinum-resistant
group.
In our patient series, PLD given at any point indeed
translated in a trend to worse outcome in term of both
PFS and OS if compared to patients that never received
this agent. While clinical trials indicated that PLD is better
tolerated as compared to other drugs, no difference in tox-
icity was observed in the current study. In our series, 16
platinum-sensitive patients were treated according to CP
schedule [20] and 6 patients received PLD. The latter
group however, experienced a worse outcome. The com-
mon practice of PLD usage in the platinum-sensitive
setting has been defined on subgroup analysis of major
randomized trials. Indeed, some reports showed a 2
months advantage for PLD compared to topotecan in
terms of PFS in platinum-sensitive subgroup only [26].
Subsequently, the non-inferiority phase III Calypso trial
compared carboplatin-PLD (CD) vs carboplatin-paclitaxel
(CP) in patients with platinum-sensitive recurrent OC. In
this trial the primary end-point (PFS) was met and a su-
periority for CD regimen was suggested. However, this
conclusion is not appropriate in the light of the non-
inferiority trial design. Indeed, reported results are not


















All lines treatment (PLD group)
All lines treatment (no-PLD group)
Figure 3 Kaplan Meier overall survival: PLD treatment in all
lines treatment.in clinical practice. The cornerstone of platinum-sensitive
OC treatment is currently represented by re-challenge
with platinum which is clearly effective, with a response
rate of about 50-60%. Meaningfully, the anti-VEGF mono-
clonal antibody bevacizumab is the only agent able to pro-
duce an improvement of 4 months in terms of PFS in
combination to platinum-containing second line treat-
ment [31]. In the platinum-resistant setting topotecan or
gemcitabine may represent an adequate option despite a
low response rate and a moderate bone marrow toxicity.
Several trials compared PLD to gemcitabine in platinum-
refractory patients and/or partially platinum-sensitive
patients without showing advantage for PLD, but only a
trend in terms of PFS for the subgroup of patients with a
platinum-free interval (PFI) between 7 and 12 months [28].
In our experience, 18 patients with a partially platinum-
sensitive status undergone a second line therapy. Of these,
13 patients were treated with a PLD-based schedule (80%
of them in combination with trabectedine, TB) whereas 5
patients received other agents. Some authors demon-
strated that TB in addition to PLD produces a 3 monthsTable 4 Toxicity in subsequent lines of treatment
(Grade ≥ 2)




Hand–foot syndrome 5% 0%
Oral toxicity 5% 3%
Neurological toxicity 1% 7%
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in PLD-free group had a better outcome in terms of both
PFS and OS (the small sample size may account for the
lack of statistical significance).
Our study presents some limitations such as the small
sample of patients, the heterogeneous therapeutic strat-
egies, the long enrollment time, with the possible occur-
rence of selection bias. Moreover, our medical records do
not include data about quality of life, an important factor
in palliative setting. However, our findings are in agree-
ment with a small retrospective study which included 43
patients treated with PLD and indicated only a marginal
benefit in terms of survival for PLD in the platinum-resist-
ant/refractory setting despite a considerable toxicity [33].
Furthermore it is important to underline that none of
major trials reported a real advantage for PLD if compared
to any other drug in terms of OS. Surprisingly, a recent
phase III trial which compared PLD to patupilone
showed a limited improvement in terms of OS for
PLD in platinum-refractory OC [34]. These findings are
difficult to interpretate taking into account the limited ex-
perience on patupilone. Interestingly, the AURELIA trial,
designed for the platinum-refractory setting, investigated
the effect of bevacizumab addition to single agent chemo-
therapy including PLD. In this trial the anti-VEGF mono-
clonal antibody produced almost a doubling (3.4 vs 6.7
months) in PFS but this advantage was indeed more rele-
vant for weekly paclitaxel if compared to PLD and topote-
can [35].
Our findings need to be considered in the general sce-
nario of anthracycline-based treatment of OC. Recently, a
report demonstrated an advantage in terms of PFS for
PLD vs Olaparib in platinum-refractory patients with
identified BRCA mutations, [36]. Moreover, others studies
reported a correlation between functional homologous re-
combination deficiency (HRD) and clinical benefit from
antracycline [37]. We did not find, however, any advantage
from the administration of PLD in patients not selected
for BRCA1 mutational status. During the last years, sev-
eral trials debunked anthracycline role in the management
of OC for a no clear advantage in efficacy at cost of an
increased toxicity [38,39].
In particular, different trials evaluated the actual cost/
effectiveness of chemotherapy beyond first line treatment.
The effectiveness of chemotherapy is correlated to PFI:
in platinum-sensitive patients PLD is cost/effective com-
pared with paclitaxel or topotecan but less cost/effective
if compared with carboplatin/paclitaxel combination; in
platinum-refractory patients best supportive care could be
cost/effective compared to PLD, topotecan or gemcitabine
combination in unfit patients [40,41].
In conclusion, our retrospective experience in a consecu-
tive series of serous papillary OC challenges the current
believes on PLD activity in OC. Further prospective studiesare needed to confirm our results, and molecular analysis
as well as investigations on the peritoneal microenviron-
ment are eagerly awaited to shed light on the molecular
basis of the response to PLD, in order to identify patients
who would gain benefit from the treatment with this agent.
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